A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 microg or 30 microg ethinylestradiol in combination with levonorgestrel on bone mineral density.
D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D003094:Collagen / Q000187:drug effects / Q000652:urine; D024042:Collagen Type I; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D003546:Cysteine Endopeptidases / Q000097:blood / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004893:Erythema Nodosum / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008234:Lynestrenol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D010455:Peptides / Q000187:drug effects / Q000652:urine; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000139:chemically induced; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
D024042:Collagen Type I; D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D016912:Levonorgestrel; D003094:Collagen; D003546:Cysteine Endopeptidases; C076935:Tc 120 proteinase; D008234:Lynestrenol